Subscribe to RSS
Download PDF
DOI: 10.1055/s-0037-1613821
Mutations in the R2 FV Gene Affect the Ratio between the Two FV Isoforms in Plasma
Publication History
Received
06 September 1999
Accepted after resubmission
17 November 1999
Publication Date:
14 December 2017 (online)
Summary
Molecular genetics and biochemical studies were performed in homozygotes for the R2 allele (4070G) in the factor V gene, most of them affected by coronary artery disease. Novel polymorphisms (G642T, 156Ser; T1328C, 385Met/Thr), among which a functional candidate (A6755G, 2194Asp/Gly) located in the C2 domain of FV, were identified in the R2 gene. In chromatographic studies R2 FV appeared qualitatively identical to normal FV. However, a relative increase of the more thrombogenic and more glycosylated FV isoform (FV1) was observed in plasma of 2194Gly homozygotes (mean FV1/FV2 ratio 0.71, 95% CI 0.66-0.77) as compared to R2-free controls (0.37, 95% CI 0.34-0.40). We conclude that carriership of the R2 FV gene is associated with an imbalance between the two functionally different FV isoforms, and propose that genetically determined differential glycosylation of FV could represent a novel mechanism of thrombotic disease.
-
References
- 1 Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
- 2 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
- 3 Rosing J, Tans G. Coagulation factor V: an old star shines again. Thromb Haemost 1997; 78: 427-33.
- 4 Lunghi B, Iacoviello L, Gemmati D, di Iasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new polymorphic markers in the FV gene: association with FV levels in plasma. Thromb Haemost 1996; 75: 45-8.
- 5 Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Man-nucci PM. A Factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
- 6 Faioni EM, Franchi F, Bucciarelli P, Margaglione M, De Stefano V, Casta-man G, Finazzi G, Mannucci PM. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (Factor V Leiden). Blood 1999; 94: 3062-6.
- 7 Alhenc-Gelas M, Nicaud V, Gandrille S, van Dreden P, Amiral J, Aubry ML, Fiessinger JN, Emmerich J, Aiach M. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999; 81: 193-7.
- 8 Castoldi E, Rosing J, Lunghi B, Hoekema L, Girelli D, Mingozzi F, Ferra-resi P, Friso S, Corrocher R, Tans G, Bernardi F. Factor V gene mutations (R2 gene) are associated with coronary artery disease in elderly people. Thromb Haemost 1999; 82 (suppl) 509 (abstr)
- 9 Rosing J, Bakker HM, Thomassen MCLGD, Hemker HC, Tans G. Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem 1993; 268: 21130-6.
- 10 Nicolaes GAF, Villoutreix BO, Dahlbäck B. Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. Biochemistry 1999; 38: 13584-91.
- 11 Hoekema L, Nicolaes GAF, Hemker HC, Tans G, Rosing J. Human factor Va1 and Va2: properties in the procoagulant and anticoagulant pathways. Biochem 1997; 36: 3331-5.
- 12 Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84: 4846-50.
- 13 Shen NLL, Fan ST, Pyati J, Graff R, LaPolla RJ, Edgington TS. The serine protease cofactor factor V is synthesized by lymphocytes. J Immunol 1993; 150: 2992-3001.
- 14 Bayston TA, Ireland H, Olds RJ, Thein SL, Lane DA. A polymorphism in the human coagulation factor V gene. Hum Mol Genet 1994; 03: 2085.
- 15 Ortel TL, Devore-Carter D, Quinn-Allen MA, Kane WH. Deletion analysis of recombinant human factor V. J Biol Chem 1992; 267: 4189-98.
- 16 Kalafatis M, Rand MD, Mann KG. Factor Va-membrane interaction is mediated by two regions located on the light chain of the cofactor. Biochem 1994; 33: 486-93.
- 17 Villoutreix BO, Bucher P, Hofmann K, Baumgartner S, Dahlbäck B. Molecular models for the two discoidin domains of human blood coagulation factor V. Journal of Molecular Modeling 1998; 04: 268-75.
- 18 Pellequer JL, Gale AJ, Griffin JH, Getzoff ED. Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding mode for FV and FVIII C2 domains. Blood Cells Mol Dis 1998; 24: 448-61.
- 19 Pittman DD, Tomkinson KN, Kaufman RJ. Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem 1994; 269: 17329-37.
- 20 Hortin GL. Sulfation of tyrosine residues in coagulation factor V. Blood 1990; 76: 946-52.
- 21 Váradi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: Influence of the factor VR506Q mutation. Thromb Haemost 1996; 76: 208-14.